top of page
32200c5c-7c4c-438f-a9df-3119a2398bf2.png
Autchmaber1.png
ai-cvd.png
AI-CVD Summary
Coronary Calcification
816_aicvd (8)_4_edited.jpg
‌ Aortic Calcification
ٍEpicardial Fat _edited.jpg
Epicardial Fat
816_aicvd (8)_5_edited.jpg
Cardiac Chambers
816_aicvd (8)_7_edited.jpg
Aorta & PA Size
816_aicvd (8)_10_edited.jpg
Lung LAI
iScreen Shoter - 20261028172009135.jpg
Lung HAI
816_aicvd (8)_11_edited.jpg
Liver Fat
816_aicvd (8)_12_edited.jpg
Muscle & Visceral Fat
816_aicvd (8)_13_edited.jpg
Bone Density
Frame 1000008569.png
Frame 1000008568.png
4acc1a9d-ced8-4f58-a79e-cd2ac6fe752e.png
Frame 1410148109.png
Frame 100000825.png
Frame i1000008267.png
Frame 1410148108.png
Frame 10000082699.png
Fra 1000008266.png
Frame 1000i008268.png
Frame 1410148110.png
Frame 100070.png
Frame 1410148111.png
valve.png

AutoLung AI: Expanding the Future of Lung Cancer Detection Beyond Traditional Screening

Jul 15
1 min read

Updated: Jul 17






AutoLung AI is an advanced artificial intelligence platform designed to improve lung cancer detection and long-term risk prediction using a wide range of CT imaging studies—not only dedicated low-dose lung cancer screening CT, but also routine chest CT, coronary artery calcium (CAC) scans, and coronary CT angiography (CCTA).

Unlike conventional approaches that primarily focus on pulmonary nodules, AutoLung AI integrates whole-lung imaging biomarkers with nodule-level analysis to provide a more comprehensive assessment of lung cancer likelihood. The platform has demonstrated the ability to identify cancers that may be missed by current Lung-RADS classification, outperform traditional nodule-based assessment, and provide meaningful prediction of future lung cancer risk years before diagnosis.

One of the most significant advantages of AutoLung AI is its ability to transform millions of existing non-screening CT examinations into valuable opportunities for opportunistic lung cancer detection. This includes individuals who fall outside current screening eligibility criteria, such as never-smokers and many former smokers, helping address important gaps in today's screening strategies.

This presentation introduces the clinical rationale, AI architecture, validation studies, and future vision of AutoLung AI, demonstrating how artificial intelligence can support earlier detection, better risk stratification, and ultimately improve patient outcomes.

Download the complete presentation below to explore the full methodology, validation results, and clinical evidence behind AutoLung AI.


Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png
autoliver patent.png
iScreen Shoter - 20261104171348520.jpg

©2026 HeartLung Corporation. All Rights Reserved. U.S. Patent Nos. 12,620,494; 12,599,350; 11,610,686. Licensed U.S. Patent Nos. 9,119,590 and 10,695,022. U.S. Patent Applications Pending: 19/390,544; 19/403,750; 19/643,672; 19/728,738; 19/741,766; 18/652,123; 18/771,542; 19/390,629; 19/417,345; 19/467,802; 19/565,385; 19/682,416; 19/690,066. International PCT Applications: PCT/US2025/058510; PCT/US2025/061047; PCT/US2025/058505; PCT/US2026/013566; PCT/US2026/024304. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoLiver, AutoChamber, AutoLung and other product names and trademarks displayed on this website are protected by applicable intellectual property laws. All rights reserved.

bottom of page